Health Canada Approves Lynparza in Combination with Abiraterone and Prednisone or Prednisolone for Patients with BRCA Mutated Metastatic Castration-Resistant Prostate Cancer

Health Canada has granted a Notice of Compliance with Conditions for Lynparza® in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious germline and/or somatic BRCA mutated metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.